Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tegoprubart - Eledon Pharmaceuticals

Next Previous
Drug Profile

Tegoprubart - Eledon Pharmaceuticals

Alternative Names: Anti-CD40 ligand monoclonal antibody - ALS Therapy Development Institute/Eledon Pharmaceuticals; Anti-CD40 ligand monoclonal antibody - Eledon Pharmaceuticals; Anti-CD40L - ALS Therapy Development Institute; AT-1501

Latest Information Update: 04 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALS Therapy Development Institute
  • Developer Eledon Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Allotransplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Renal transplant rejection
  • Phase I Xenotransplant rejection
  • Preclinical Liver transplant rejection
  • No development reported Autoimmune disorders
  • Discontinued Allotransplant rejection; IgA nephropathy

Most Recent Events

  • 04 Apr 2024 Discontinued - Phase-II for IgA nephropathy (In the elderly, In adults) in Philippines, Poland, Sri Lanka, United Kingdom, Croatia, Thailand (IV)
  • 21 Mar 2024 Efficacy data from a phase Ib/II trial in Renal transplant rejection released by Eledon Pharmaceuticals
  • 04 Jan 2024 University of Chicago in collaboration with Juvenile Diabetes Research Foundation and Cure Alliance plans a phase I/II trial for Islet cell transplant rejection in USA (Parenteral, injection) (NCT06305286)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top